Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells. | Int J Oncol;37(2): 419-28, 2010 Aug. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.

Jeon, Heui Sook; Ahn, Mee Young; Park, Ji Hye; Kim, Tae Hyung; Chun, Pusoon; Kim, Won Hee; Kim, Jungsu; Moon, Hyung Ryong; Jung, Jee H; Kim, Hyung Sik.

Affiliation

Jeon HS; College of Pharmacy, Pusan National University, Jangjeon-dong, Geumjeong-gu, Busan 609-735, South Korea.

Int J Oncol ; 37(2): 419-28, 2010 Aug.

Article in En | MEDLINE | ID: mdl-20596669

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Carcinoma / Histone Deacetylase Inhibitors / Antineoplastic Agents Limits: Female / Humans Language: En Journal: Int J Oncol Journal subject: NEOPLASIAS Year: 2010 Document type: Article Affiliation country: Corea del Sur

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Carcinoma / Histone Deacetylase Inhibitors / Antineoplastic Agents Limits: Female / Humans Language: En Journal: Int J Oncol Journal subject: NEOPLASIAS Year: 2010 Document type: Article Affiliation country: Corea del Sur